Company Overview - SI-BONE, Inc. is a global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company specializes in biomechanical design and innovations specific to anatomy, focusing on spinopelvic anatomy [3] - Since its inception in 2009, SI-BONE has supported over 140,000 procedures, backed by clinical evidence including four randomized controlled trials and over 180 peer-reviewed publications [3] Upcoming Events - SI-BONE will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA, hosting a fireside chat on March 2, 2026, at 7:30 a.m. Pacific Time [1] - Investors can listen to the conference call by registering through a provided link, with live audio available on the company's website [2]

Si-Bone (SIBN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 23, might help the stock move higher if these key numbers are better than expectat ...

Core Viewpoint - SI-BONE, Inc. is set to report its financial results for Q4 and the full year of 2025 on February 23, 2026, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] Company Overview - SI-BONE, Inc. is recognized as the global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company specializes in additive manufacturing, leading to a technology platform with applications in SI joint fusion, adult spinal deformity, and pelvic trauma [3] - Since its inception in 2009, SI-BONE has facilitated over 140,000 procedures, supported by a robust body of clinical evidence including four randomized controlled trials and over 200 peer-reviewed publications [3]

Financial Performance - SI-BONE, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year 2025, details to be provided in the attached press release[6] - The financial statements and exhibits related to the earnings report are included in the Form 8-K filing[8] Investor Relations - The company plans to meet with investors and analysts during the week of January 12, 2026, to discuss performance using presentation materials[7]

Core Insights - SI-BONE, Inc. anticipates worldwide revenue for Fiscal Year 2025 to be between $200.8 million and $200.9 million, indicating a growth of approximately 20% [1][6] - The company reported fourth quarter revenue between $56.2 million and $56.3 million, reflecting a growth of around 15% compared to the prior year [6] - U.S. revenue for the fourth quarter is projected to be between $53.3 million and $53.4 million, showing a growth of about 14% [6] Fiscal Year 2025 Summary - The preliminary revenue for Fiscal Year 2025 is expected to be between $200.8 million and $200.9 million, with a growth rate of approximately 20% [1][6] - U.S. revenue for the fiscal year is projected to be between $190.9 million and $191.0 million, representing a growth of around 21% [6] Fourth Quarter 2025 Summary - The fourth quarter revenue is estimated to be between $56.2 million and $56.3 million, which is a growth of approximately 15% year-over-year [6] - The U.S. revenue for the fourth quarter is expected to be between $53.3 million and $53.4 million, indicating a growth of about 14% [6] - The company has approximately 1,640 active physicians in the U.S., an increase of 250 physicians, representing an 18% growth [6] - Cash and cash equivalents are estimated to be around $147.7 million, implying a net cash generation of approximately $2.0 million in the quarter [6] Company Overview - SI-BONE, Inc. is recognized as a global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company has a strong expertise in additive manufacturing, leading to market-leading applications in areas such as SI joint fusion, adult spinal deformity, and pelvic trauma [3] - Since its inception in 2009, SI-BONE has supported over 140,000 procedures, backed by a substantial body of clinical evidence including four randomized controlled trials and over 200 peer-reviewed publications [3]

Company Overview - SI-BONE, Inc. (NASDAQ:SIBN) develops and sells medical devices targeting musculoskeletal disorders in the sacropelvic area, including minimally invasive implants for sacroiliac joint dysfunction, pelvic trauma, and spinal support [2]. Investment Sentiment - The company has been highlighted as a speculative investment opportunity, with notable interest from investment commentators, indicating a growing recognition in the market [1]. - There is a suggestion that while SI-BONE has potential, certain AI stocks may offer greater upside potential and carry less downside risk, indicating a competitive investment landscape [3].

Core Insights - SI-Bone Inc. (NASDAQ:SIBN) shares experienced a 3.65% increase in after-hours trading, closing at $21.14, following a regular trading session close of $20.40, which was up 2.15% [1] Executive Share Sales - Three executives sold shares to cover tax obligations from restricted stock unit vesting, with Chief Financial Officer Anshul Maheshwari selling 5,229 shares for a total of $102,710.61 [2] - Senior Vice President and Chief Legal Officer Michael Pisetsky sold 3,460 shares totaling $67,896.05, while President of Commercial Operations Anthony Recupero sold 3,677 shares for $72,143.84 [3] Trading Metrics and Performance - SI-Bone has a Relative Strength Index (RSI) of 62.48 and a 12-month return of 44.48%, indicating strong performance and an upward trend [5] - The company's market capitalization is approximately $885.2 million, with shares trading between a 52-week high of $21.06 and a low of $12.50 [5] - Currently, SIBN is trading at 92.2% of its 52-week range, suggesting it is near its annual highs [6] Analyst Ratings - Analysts from Truist Securities, Canaccord Genuity, Needham & Company, and Morgan Stanley have maintained bullish ratings and raised price targets for SIBN [6] - Benzinga's Edge Stock Rankings indicate a positive price trend for SIBN across all time frames [7]

Core Viewpoint - Needham analyst David Saxon has raised the price target for SI-Bone (SIBN) to $27 from $24 while maintaining a Buy rating on the shares, indicating confidence in the company's growth potential [1] Group 1: Price Target and Ratings - The price target for SI-Bone has been increased to $27 from $24 [1] - SI-Bone has been added to Needham's 'Conviction List' and is named as the firm's '2026 Top Pick' [1] Group 2: Growth Potential - Needham believes SI-Bone can deliver potential upside to estimates in the near term, which is expected to enhance profitability [1] - Upcoming product launches are anticipated to drive active surgeon adoption across SI-Bone's portfolio, leading to higher utilization [1]

Core Viewpoint - SiBone (SIBN) is identified as a potential stock pick due to a recent "golden cross" event, indicating a bullish trend from a technical perspective [1]. Technical Analysis - A "golden cross" occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), suggesting a potential bullish breakout [2]. - The formation of a golden cross involves three stages: a downtrend that bottoms out, the crossover of moving averages, and subsequent upward momentum [3]. - The golden cross is contrasted with a "death cross," which indicates potential bearish momentum [3]. Performance Metrics - SIBN has experienced a rally of 26.7% over the past four weeks, indicating strong upward momentum [4]. - Currently, SIBN holds a 3 (Hold) rating on the Zacks Rank, suggesting it may be poised for further breakout [4]. - Earnings expectations for SIBN have improved, with five upward revisions and no downward changes in the last 60 days, leading to an increase in the Zacks Consensus Estimate [4]. Investment Consideration - Given the significant technical indicators and positive earnings estimate movements, SIBN is recommended for inclusion on investors' watchlists [6].

Summary of SI-BONE FY Conference Call (December 02, 2025) Company Overview - **Company**: SI-BONE (NasdaqGM:SIBN) - **Industry**: Medical Technology, specifically focused on orthopedic devices and surgical solutions Key Points and Arguments Financial Performance - **Q3 Revenue Growth**: Achieved a total revenue growth of **21%** year-over-year, indicating strong business performance [12] - **Physician Engagement**: Notable **27%** increase in the number of physicians performing procedures, with **330 more surgeons** participating, totaling over **1,500 surgeons** in Q3 2025 [12] - **Profitability**: The company has reported four consecutive quarters of adjusted EBITDA profitability and has reached net cash break-even in recent quarters [12] Product and Market Strategy - **Innovative Products**: The company has established a reputation for innovation, with over **180 peer-reviewed publications** supporting the safety and efficacy of its products [14] - **Sales Strategy**: Utilizes a hybrid sales approach with **88 territory managers** and over **300 third-party agents** to expand market reach [13] - **Diversification**: The company has diversified its product offerings beyond SI Joint Fusion to include pelvic fixation and other breakthrough devices, mitigating risks associated with patent expirations [21][22] Patent and Competitive Landscape - **Patent Expiration Concerns**: Management expressed confidence regarding patent expirations, noting that the majority of sales come from products with patents extending through **2034-2035** [21] - **Competitive Positioning**: The company is focused on developing a robust pipeline of innovative products to maintain competitive advantages [22] Future Growth Opportunities - **Procedure Expansion**: Currently, **25%** of SI joint surgeons are performing multiple procedure types; there is potential to increase this to **50%** [30] - **New Product Launches**: A new product targeting a significant unmet clinical need in spine surgery is expected to launch in the second half of **2026**, which could further enhance growth [31] - **Market Penetration**: The company aims to increase its penetration in the SI Joint Fusion market from **10%** to potentially **15-20%** over time [60] Reimbursement and Regulatory Environment - **Reimbursement Increases**: Recent changes in reimbursement policies are expected to provide tailwinds, including a **30%** higher reimbursement for pelvic ring fracture cases and a **17%** increase for SI Joint Fusion procedures starting January 1, 2026 [52][53] - **Outpatient Opportunities**: The shift of many inpatient procedures to outpatient settings presents additional growth opportunities, particularly for the Granite product [54] Gross Margin and Operational Efficiency - **Gross Margin Performance**: The company reported gross margins exceeding **78%**, driven by better-than-expected average selling prices (ASP) and supply chain efficiencies [80] - **Future Margin Expectations**: Management anticipates maintaining gross margins around **78%** over the next few years, with potential for improvement as new products scale [81] Investment and R&D Focus - **Long-term Growth Strategy**: The company plans to continue investing in R&D to support its pipeline of new products, particularly in the area of compromised bone solutions [91] - **Operating Leverage**: Expected operating leverage of **1.5 times** revenue growth over operating expenses, indicating a focus on maintaining healthy adjusted EBITDA margins [90] Additional Important Insights - **Market Size**: The Granite product targets a **billion-dollar** market, with significant potential for growth as the company expands its offerings [37] - **Sales Force Integration**: New products are expected to be easily integrated into the existing sales force, potentially enhancing overall market attention and sales [47] This summary encapsulates the key insights from the SI-BONE FY Conference Call, highlighting the company's strong performance, innovative strategies, and future growth potential in the medical technology sector.